Michelle Dipp's Investment History & Timeline
Michelle Dipp, MD PhD is a Co-Founder and Managing Partner of Biospring Partners. She has over a decade of private equity and venture capital expertise in life sciences.
Michelle Dipp Affiliation: Biospring Partners
Amt. Raised (total): $10,000,000
Round of Funding: Post IPO Equity
Lead Investor: Yes
About Abzena: Abzena provides complementary services to organizations involved in the development of bio-pharmaceuticals.
July 28 , 2020
Press Release:
- Biospring Partners Backs Drug Developer and Manufacturer Abzena
- Founded by Dipp and Lum, growth firm Biospring to invest in services, tools software
- Abzena Reveives $10M Investment from Biospring Partners
- New York backer injects $10 million into Abzena
- Biospring Partners backs UK-based drug developer Abzena in debut deal
- Abzena Raises 10 Million Growth Capital from Biospring
- Abzena Receives Growth Capital Investment from Newly Launched Biospring Partners
- Biospring Partners invests $10M in Welsh Carson-owned Abzena
- Abzena raises growth capital from newly launched Biospring Partners
- Abzena Receives Growth Capital Investment from Newly Launched Biospring Partners
Michelle Dipp Affiliation: General Atlantic
Amt. Raised (total): $70,000,000
Round of Funding: Series F
About Ginkgo Bioworks: Ginkgo Bioworks is a developer of biological engineering products and custom microbes across multiple markets.
Michelle Dipp Affiliation: General Atlantic
Amt. Raised (total): $130,000,000
Round of Funding: Series B
Lead Investor: Yes
About Immunocore: Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies.
September 19, 2019
Press Release:
- Ginkgo Bioworks Launches $350M Private Investment Vehicle
- Ginkgo Bioworks Raises $290 Million in Series E Financing to Grow its Platform for Cell Programming
- Ginkgo Bioworks: $290 Million In Funding To Expand Cell Programming Platform
- Synthetic Biology Unicorn Ginkgo Bioworks Raises An Additional $290 Million
- Synthetic Biology Company Ginkgo Bioworks Tops $4 Billion Valuation, Pushing It’s Ph.D. Founders’ Stakes To Some $250 Million Each
Michelle Dipp Affiliation: General Atlantic
Amt. Raised (total): $290,000,000
Round of Funding: Series E
About Ginkgo Bioworks: Ginkgo Bioworks is a developer of biological engineering products and custom microbes across multiple markets.
Michelle Dipp Affiliation: General Atlantic
Amt. Raised (total): $180,000,000
Round of Funding: Series B
Lead Investor: Yes
About Ocumension Therapeutics: Ocumension Therapeutics is a pharmaceutical platform dedicated to identifying, developing, and commercializing ophthalmic therapies.
June 18, 2019
Press Release:
Michelle Dipp Affiliation: General Atlantic
Amt. Raised (total): $60,000,000
Round of Funding: Series B
Lead Investor: Yes
About PathAI: PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient.
Michelle Dipp Affiliation: General Atlantic
Amt. Raised (total): $275,000,000
Round of Funding: Series D
About Ginkgo Bioworks: Ginkgo Bioworks is a developer of biological engineering products and custom microbes across multiple markets.
Michelle Dipp Affiliation: Longwood Fund
Amt. Raised (total): $14,100,000
Round of Funding: Series C
Lead Investor: No
About Channel Medsystems: Channel Medsystems is a clinical-stage medical technology engaged in the development of proprietary cryo-ablation delivery technologies.
Michelle Dipp Affiliation: Longwood Fund
Amt. Raised (total): $30,400,000
Round of Funding: Series B
Lead Investor: No
About Pulmocide: Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
March 20 , 2017
Press Release:
Michelle Dipp Affiliation: Longwood Fund
Amt. Raised (total): $19,150,000
Round of Funding: Series A
Lead Investor: Yes
About Axial Biotherapeutics: Axial Biotherapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System.
Michelle Dipp Affiliation: Longwood Fund
Amt. Raised (total): $2,000,000
Round of Funding: Series C
Lead Investor: No
About Channel Medsystems: Channel Medsystems is a clinical-stage medical technology engaged in the development of proprietary cryo-ablation delivery technologies.
September 22, 2015
Press Release:
September 10, 2014
Press Release:
Michelle Dipp Affiliation: Longwood Fund
Amt. Raised (total): $15,000,000
Round of Funding: Series B
Lead Investor: Yes
About Colorscience: Colorscience is a luxury aesthetic makeup products line in the medical and resort spa sectors.